



22:1

ISLAND HAZE

Cannabis Based Medicinal Product (CBMP) Approved for prescription use in the UK
Manufacturer EU GMP NO: IWSF.405.125.2021.IP.2


Laboratory Analysis Values: Approx. 22% Tetrahydrocannabinol (THC) <1% Cannabidiol (CBD)

Profile: Sativa Dominant Hybrid

Formulation: Flos/whole dried Cannabis Flowers

Route of Administration: For inhalation via vaporiser as directed by physician

Prevalent Terpenes and Ingredients



Titration Guide

- There is no uniform starting dose nor dosing information for cannabis products.
- Patients are recommended to slowly titrate up to find their optimal dose for maximal therapeutic and minimal adverse effects.
- Onset of effects are within seconds to minutes.
- Full effects peak within 30 minutes and will last up to 6 hours or longer.
- Adverse effects should be reported: www.mhra.gov.uk/yellowcard.